Maker of Mounjaro and Zepbound tirzepatide
Eli Lilly is the Indianapolis-based pharma powerhouse behind tirzepatide (Mounjaro for diabetes, Zepbound for obesity) — a dual GLP-1/GIP receptor agonist peptide that outperforms semaglutide on weight loss. Lilly's next-generation pipeline includes retatrutide (triple agonist in Phase 3) and orforglipron (oral small-molecule GLP-1). The company briefly became the most valuable US healthcare company on the back of its peptide obesity franchise.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| Mounjaro (tirzepatide) | Type 2 Diabetes | FDA Approved | GLP-1/GIP Dual |
| Zepbound (tirzepatide) | Obesity | FDA Approved | GLP-1/GIP Dual |
| Retatrutide | Obesity | Phase 3 | GLP-1/GIP/Glucagon Triple |
| Orforglipron | Obesity / T2D | Phase 3 | Oral small-molecule GLP-1 |
| Eloralintide | Obesity | Phase 2 | Amylin analog |
A 2026 investor guide to GLP-1 stocks: Novo Nordisk vs Eli Lilly, pipeline, market cap, risks, and the obesity drug challengers to watch.
Eli Lilly acquired Verve Therapeutics for $1.3 billion in July 2025 — the biggest signal yet that big pharma believes in one-time genetic cures for chronic diseases.